Viewing Study NCT00390936



Ignite Creation Date: 2024-05-05 @ 5:09 PM
Last Modification Date: 2024-10-26 @ 9:28 AM
Study NCT ID: NCT00390936
Status: COMPLETED
Last Update Posted: 2011-01-25
First Post: 2006-10-20

Brief Title: A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
Sponsor: Bristol-Myers Squibb
Organization: Bristol-Myers Squibb

Study Overview

Official Title: Phase I Multiple Ascending Dose Study to Determine the Safety Pharmacokinetics and Pharmacodynamics of BMS-582664 in Japanese Patients With Advanced or Metastatic Solid Tumors
Status: COMPLETED
Status Verified Date: 2010-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to assess the dose limiting toxicity DLT of BMS-582664 and the maximum tolerated doseMTD in subjects with advanced or metastatic solid tumors
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None